In-vitro Release and Stability Studies of Raloxifene Loaded Solid-Lipid Nanoparticle

Objective: Raloxifene HCl (RLX) show a low oral bioavailability (<2%) in human due to its poor solubility and extensive (>90%) first-pass metabolism. To overcome these limitations, the present investigation deals with the development of Compritol 888 ATO based optimized RLX-loaded solid lipid nanoparticle (SLN) .

Methods: Compritol 888 ATO-based RLX-loaded optimized solid lipid nanoparticle (SLN) were formulated using oil in water microemulsion method. Drug-excipients compatibility was confirmed through a powder X-ray diffraction study. The optimized SLN was characterized for particle size and drug release.

Results: Drug-excipients compatibility was confirmed powder X-ray diffraction study. As per the desirability function value (0.959) the optimized formulation has the size and EE of 168.97 nm and 93.14%. In-vitro study showed a sustained release of RLX from the optimized SLNs. The optimized formulation was found stable for 180 days.

Conclusion: The high biocompatibility, biodegradability, ability to protect drug in GIT and sustained release properties make SLNs an ideal candidate to resolve poor oral bioavailability challenges.